Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Raising the bar for Randomized Trials involving Artificial Intelligence: The SPIRIT-AI and CONSORT-AI Guidelines. The Journal of investigative dermatology Taylor, M., Liu, X., Denniston, A., Esteva, A., Ko, J., Daneshjou, R., Chan, A., SPIRIT-AI and CONSORT-AI Working Group 2021

Abstract

Artificial intelligence (AI)-based applications have the potential to improve the quality and efficiency of patient care in dermatology. Unique challenges in the development and validation of these technologies may limit their generalizability and real-world applicability. Before widespread adoption of AI interventions, randomized trials should be conducted to evaluate their efficacy, safety, and cost effectiveness in clinical settings. The recent SPIRIT-AI (Standard Protocol Items: Recommendations for Interventional Trials - AI extension) and CONSORT-AI (Consolidated Standards of Reporting Trials - AI extension) guidance provide recommendations for reporting the methods and results of trials involving AI interventions. High-quality trials will provide gold standard evidence to support the adoption of AI for the benefit of patient care.

View details for DOI 10.1016/j.jid.2021.02.744

View details for PubMedID 33766511